摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+)-7,8-di-epi-altholactone | 124868-11-7

中文名称
——
中文别名
——
英文名称
(+)-7,8-di-epi-altholactone
英文别名
(+)-isoaltholactone;Isoaltholactone;(2S,3S,3aS,7aS)-3-hydroxy-2-phenyl-2,3,3a,7a-tetrahydrofuro[3,2-b]pyran-5-one
(+)-7,8-di-epi-altholactone化学式
CAS
124868-11-7;65408-91-5;114488-17-4;114488-19-6;120019-23-0;120019-27-4;124868-12-8
化学式
C13H12O4
mdl
——
分子量
232.236
InChiKey
ZKIRVBNLJKGIEM-XYJRDEOASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    102-103 °C
  • 沸点:
    490.4±45.0 °C(Predicted)
  • 密度:
    1.336±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:0c14e8be5ef6add5181db413744c91f7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    (+)-Altholactone [(+)-Goniothalenol] 和三种立体异构体的全合成及其对几种肿瘤细胞系的细胞毒性
    摘要:
    (+)-altholactone [(+)-goniothalenol] (1) 的对映特异性全合成是一种新型四氢呋喃 5-one,对多种肿瘤细胞系具有显着的细胞毒性,已通过使用 L-阿拉伯糖作为多余的起始材料实现。关键的四氢呋喃形成是通过用硅胶处理 (2S,3R)-4,5-epoxy-5-phenyl-1,2,3-pentanetriol 1,3-benzylidene acetals 8 和 8' 的非对映异构混合物来实现的。主要环化产物 (2S,3R,4S,5S)-2-(羟甲基)-5-苯基四氢呋喃-3,4-二醇的 O,O'-亚苄基衍生物在 C-4 和 C-5 处同时进行立体化学反转(11), 到 2S,3R,4R,5R 非对映异构体 10 是通过硼氢化 (2S,3S)-3-羟基-2-(羟甲基)-5-苯基-2,3-二氢呋喃 O,O'-衍生自 11 的亚苄基衍生物 (18)。10 的 Pfitzner-Moffatt
    DOI:
    10.1246/bcsj.62.2328
点击查看最新优质反应信息

文献信息

  • A concise and stereoselective synthesis of both enantiomers of altholactone and isoaltholactone
    作者:J.S. Yadav、G. Rajaiah、A.Krishnam Raju
    DOI:10.1016/s0040-4039(03)01413-8
    日期:2003.7
    A concise and flexible stereoselective route to synthesize both enantiomers of the highly functionalized α,β-unsaturated-δ-lactones, altholactone and isoaltholactone, from readily available cinnamyl alcohol is described. This approach derived its asymmetry from Sharpless catalytic asymmetric epoxidation and Sharpless asymmetric dihydroxylation reactions. The resulting diols were produced in high enantiomeric
    描述了一种简明且灵活的立体选择路线,该路线可以从容易获得的肉桂醇合成高度官能化的α,β-不饱和-δ-内酯,对内酯和异对内酯的两种对映异构体。这种方法的不对称性源于Sharpless催化不对称环氧化和Sharpless不对称二羟基化反应。所产生的二醇以高对映体过量产生,并在催化量的樟脑磺酸存在下以立体选择性方式环化。
  • Highly stereoselective synthesis of antitumor agents: both enantiomers of goniothales diol, altholactone, and isoaltholactone
    作者:Jhillu Singh Yadav、Atcha Krishnam Raju、Ponugoti Purushothama Rao、Gurram Rajaiah
    DOI:10.1016/j.tetasy.2005.08.047
    日期:2005.10
    A flexible stereoselective route to synthesize both enantiomers of the highly functionalized substituted tetrahydrofurans and α,β-unsaturated-δ-lactones, goniothales diol, altholactone, and isoaltholactone, from readily available cinnamyl alcohol is described. This approach derived its asymmetry from Sharpless catalytic asymmetric epoxidation and Sharpless asymmetric dihydroxylation reactions. The
    描述了从容易获得的肉桂醇合成高度官能化的取代的四氢呋喃的对映异构体和α,β-不饱和-δ-内酯,菊苣二醇,甲内酯和异甲内酯的对映体的灵活的立体选择性途径。这种方法的不对称性源于Sharpless催化不对称环氧化和Sharpless不对称二羟基化反应。所产生的二醇以高对映体过量产生,并在催化量的樟脑磺酸存在下以立体选择性方式环化。
  • Stereospecificity in the Au-catalysed cyclisation of monoallylic diols. Synthesis of (+)-isoaltholactone
    作者:William P. Unsworth、Kiri Stevens、Scott G. Lamont、Jeremy Robertson
    DOI:10.1039/c1cc11805f
    日期:——
    We describe a concise synthesis of (+)-isoaltholactonevia a Au-catalysed cyclisation of a monoallylic diol to form the tetrahydrofuranyl ring. Analogous cyclisations show that the stereochemical outcome is dictated by the stereochemistry of the diol substrate.
    我们描述了一种简洁的合成(+)-异阿尔酮内酯的方法,该方法通过金催化的单烯醇二醇环化反应形成四氢呋喃环。类似的环化反应显示,立体化学结果受二醇底物的立体化学影响。
  • Enantioselective total synthesis of (+)-isoaltholactone
    作者:Xiaoshui Peng、Anpai Li、Jiangping Lu、Qiaoling Wang、Xinfu Pan、Albert S.C Chan
    DOI:10.1016/s0040-4020(02)00791-3
    日期:2002.8
    A facile enantioselective route to highly functionalized α,β-unsaturated -δ-lactones has allowed for the synthesis of (+)-isoaltholactone in 6.4% overall yield from furylmethanol. This approach derived its asymmetry by applying Sharpless kinetic resolution on racemic 2-furylmethanol. The resulting pyranone was produced in high enantioexcess and was stereoselectively transformed into (+)-isoaltholactone
    到高度官能化的α,β-不饱和-δ-内酯的简便对映选择性路线已使呋喃甲醇以6.4%的总收率合成(+)-异甲内酯。该方法通过在外消旋2-呋喃甲醇上应用Sharpless动力学拆分来获得其不对称性。产生的吡喃酮以高对映体过量产生,并通过高度非对映选择性环氧化和关键的PPTS催化的分子内环化反应被立体选择性地转化为(+)-异甲内酯。
  • An olefination approach to the enantioselective syntheses of several styryllactones
    作者:Joel M Harris、George A O'Doherty
    DOI:10.1016/s0040-4020(01)00355-6
    日期:2001.6
    Sharpless catalytic asymmetric dihydroxylation to vinylfuran. The resulting diols are produced in high enantioexcess and can be stereoselectively transformed into α,β-unsaturated-δ-lactones via a short highly diastereoselective oxidation and reduction sequence. Wittig olefination or Julia olefination reactions were used to introduce the phenyl group side chain either cis or trans selectively and these
    到高度官能化的α,β不饱和δ内酯的柔性对映选择性途径,已经允许用于styryllactones的合成:altholactone,isoaltholactone,3-外延-altholactone,2-外延-altholactone和5-羟基goniothalamin在2.5,10,糠醛的总收率分别为5%,1%和13%。通过将Sharpless催化不对称二羟基化反应应用于乙烯基呋喃,此方法可得出其不对称性。所产生的二醇以高对映体过量产生,并且可以通过短的高度非对映选择性氧化和还原序列立体选择性地转化为α,β-不饱和-δ-内酯。使用维蒂希(Wittig)烯化或朱莉娅(Julia)烯化反应来引入顺式或反式的苯基侧链 选择性地将这些中间体通过选择性环氧化反应进一步精制为内酯异构体。
查看更多

同类化合物

马桑宁内酯 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 5-hydroxymethyl-3-methyl-2H-furo[2,3-c]pyran-2-one 5-fluoromethyl-2H-furo[2,3-c]pyran-2-one 5-chloromethyl-2H-furo[2,3-c]pyran-2-one 10,11-Anhydro-5-deoxy-1,2-O-isopropylidene-9-O-(methoxymethyl)-β-L-xylo-L-ido-7-undeculofuranose-(1,4)-pyranose-(7,3) 3,7-dimethyl-2H-furo[2,3-c]pyran-2-one 4R-(3αβ,3aβ,4β,5α,6β,7aβ)hexahydro-2,2-dimethyl-4,5-bis(phenylmethoxy)-6-[(phenylmethoxy)methyl]4H-furo[2,3-b]pyran-3-ol 10,10-dimethyl-5-(methylsulfanyl)-10,11-dihydro-8H-pyrano[4',3':4,5]furo[3,2-e]tetrazolo[1,5-c]pyrimidine (R)-3-((2R,3R,5aR,7R,9aS)-3-hydroxyhexahydro-2H-2,5a-methanopyrano[3,2-e][1,4]dioxepin-7-yl)-2-methylpropanenitrile 13-methyl-8,10,12-trioxapentacyclo[5.5.2.02,6.O3,11.05,9]-13-tetradecene 2,3,4,4a,7,8-Hexahydro-6H-2-(acetoxymethyl)-3,4-diacetoxy-1,9-dioxacyclohexainden-5-one 2,3,4,4a,7,8-Hexahydro-6H-2-methoxy-1,9-dioxacyclohexainden-5-one (-)-3a-methyl-3a,4-dihydro-1H,3H-furo[3,4-c]pyran-6,6,7-tricarboxylic acid 6,6-diethyl ester 7-methyl ester (+)-8-epi-altholactone 4-(perfluorophenyl)-3-phenylhexahydro-1H-furo[3,4-c]pyran [(2R,11S,12R,14R,15R,17R,19S)-19-tert-butyldiphenylsiloxymethyl-15-methyl-13,18-dioxadispiro(2H-3,6-dihydropyran-6,5'-oxolane-2',3''-bicyclo[4.3.0]nonane)-2-yl]phenylmethoxymethane (3aS,5S,9bS)-5-methyl-3,3a-dihydro-5H-furo[3,2-c]isochromene-2,6,9-(9bH)-trione (3aR,5R,7aR)-5-(2-hydroxypropan-2-yl)-7a-methylhexahydro-2H-furo[3,2-b]pyran-2-one 2,2,3b-trimethyl-7-vinyl-3a,5,7a,8a-tetrahydro-3bH-1,3,4,8-tetracyclopenta[a]indene ethyl 4-oxo-3-phenyl-3,3a,4,6-tetrahydro-1H-furo[3,4-c]pyran-3a-carboxylate methyl (2R,2aR,4aS,7aS,7bS)-2-methoxy-6-methyl-4-oxo-5-pentyl-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxacyclopenta[cd]indene-7a-carboxylate 4-nonyl-3-phenylhexahydro-1H-furo[3,4-c]pyran 3'-(4-methoxyphenyl)-7a'-methyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 3',7a'-dimethyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 2-(methylsulfanyl)-5,6-dihydro-4H-furo[2,3-b]pyran 1,1-(3-dimethylamino-3-phenylpentamethylen)-3,4-dihydro-1H-2,9-dioxafluoren 7-cyclopropyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one (4'R)-6-O-(4-cyanophenyl)-1,2,3,4-tetradeoxy-4'-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononyl)-2',3',4',5'-tetrahydro-α-D-erythro-hexopyranoso[1,2-b]furan 2,2,3,6-tetramethyl-2,3-dihydro-4H-furo[2,3-b]pyran-4-one (1aR,4aS,5R)-7-carboethoxy-5-methylethyl-tetrahydrofurano[2,3-b]3,4-dihydro-2H-pyran (3aS,4S,7aR)-ethyl 4-methyl-3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran-6-carboxylate